Edesa Biotech

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing new, safe, and effective non-steroidal alternatives for allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa Biotech's lead asset, EB01, is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis, which has demonstrated statistically significant improvement in multiple clinical studies.